

Pier Francesco Ferrucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600850/publications.pdf>

Version: 2024-02-01

77
papers

5,189
citations

201674

27
h-index

91884

69
g-index

79
all docs

79
docs citations

79
times ranked

6399
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	10.7	1,089
2	The acute promyelocytic leukemia-specific PML-RAR $\hat{\pm}$ fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. <i>Cell</i> , 1993, 74, 423-431.	28.9	583
3	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
4	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	10.7	273
5	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	30.7	256
6	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	1.6	244
7	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
8	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	2.5	151
9	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 772-781.	6.3	144
10	Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. <i>British Journal of Haematology</i> , 2007, 136, 521-538.	2.5	131
11	Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. <i>Dermatologic Therapy</i> , 2010, 23, 651-661.	1.7	123
12	Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. <i>Cancers</i> , 2021, 13, 1383.	3.7	120
13	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	4.2	118
14	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
15	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF ^{V600E} Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
16	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	2.8	76
17	Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. <i>Oncogene</i> , 1998, 16, 2905-2913.	5.9	69
18	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61

#	ARTICLE	IF	CITATIONS
19	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology, 2016, 34, 9505-9505.	1.6	50
20	High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. Journal of Nuclear Medicine, 2007, 48, 1871-1879.	5.0	49
21	High activity ⁹⁰ Yâ€ibritumomab tiuxetan (Zevalin [®]) with peripheral blood progenitor cells support in patients with refractory/resistant Bâ€cell nonâ€Hodgkin lymphomas. British Journal of Haematology, 2007, 139, 590-599.	2.5	45
22	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44
23	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1Âmillimeter in thickness: A multi-institutional study of 1524 cases. Journal of the American Academy of Dermatology, 2017, 76, 264-273.e2.	1.2	41
24	Prognostic significance of hematological profiles in melanoma patients. International Journal of Cancer, 2016, 139, 1618-1625.	5.1	40
25	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	10.7	37
26	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research, 2021, 27, 4737-4745.	7.0	35
27	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). Cancer Research, 2017, 77, CT075-CT075.	0.9	34
28	Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. European Radiology, 2019, 29, 1882-1892.	4.5	31
29	Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. European Radiology, 2017, 27, 4372-4378.	4.5	30
30	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. Journal of Clinical Oncology, 2015, 33, LBA1-LBA1.	1.6	28
31	In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocalPML/RARA orRARA/PML fusion genes. Genes Chromosomes and Cancer, 1998, 22, 241-250.	2.8	27
32	Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone<i>versus</i>chemotherapy + involved field radiotherapy. Leukemia and Lymphoma, 2009, 50, 925-931.	1.3	27
33	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget, 2017, 8, 79809-79815.	1.8	27
34	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	4.8	27
35	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2018, 97, 59-61.	2.8	22
36	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy, 2014, 14, 955-967.	3.1	20

#	ARTICLE	IF	CITATIONS
37	Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial. <i>Nutrients</i> , 2021, 13, 1931.	4.1	20
38	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6039-6046.	7.0	18
39	HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. <i>Expert Review of Vaccines</i> , 2009, 8, 1513-1526.	4.4	16
40	Maspin expression and melanoma progression: a matter of sub-cellular localization. <i>Modern Pathology</i> , 2014, 27, 412-419.	5.5	16
41	Oncophage [®] (vitespen [®]) - Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get?. <i>Hum Vaccin</i> , 2009, 5, 727-737.	2.4	13
42	Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy. <i>PLoS ONE</i> , 2013, 8, e78820.	2.5	13
43	High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. <i>Blood</i> , 2006, 108, 2720-2720.	1.4	11
44	Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. <i>Current Oncology Reports</i> , 2021, 23, 138.	4.0	11
45	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	2.8	10
46	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	1.6	9
47	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA1-LBA1.	1.6	9
48	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1395-1407.	3.1	8
49	Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 11-31.	2.1	8
50	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	3.2	8
51	A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. <i>Cells</i> , 2021, 10, 70.	4.1	8
52	Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. <i>Acta Oncol</i> , 2018, 57, 1131-1133.	1.8	7
53	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
54	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8529-8529.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Effectiveness of dabrafenib in the treatment of patients with BRAF V600E mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
56	ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma. <i>Cancers</i> , 2020, 12, 3366.	3.7	6
57	Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy. <i>European Journal of Cancer</i> , 2022, 172, 332-339.	2.8	6
58	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8513-8513.	1.6	5
59	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9035-9035.	1.6	5
60	A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9090-TPS9090.	1.6	5
61	Novel Biomarkers and Druggable Targets in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 81.	3.7	5
62	Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. <i>Blood</i> , 2007, 110, 4499-4499.	1.4	4
63	Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9596-TPS9596.	1.6	4
64	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
65	Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma. <i>Anti-Cancer Drugs</i> , 2020, 31, 652-654.	1.4	3
66	High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. <i>Blood</i> , 2007, 110, 1890-1890.	1.4	3
67	Surgery in stage IV melanoma patients: Results from a single institution.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19035-e19035.	1.6	3
68	Meta-analysis of randomized phase II-III trials evaluating triplet combinations of immunotherapy and targeted therapy for BRAF V600-mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9541-9541.	1.6	3
69	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3.	7.2	1
70	A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients (pts) with metastatic melanoma: Analysis of peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20025-e20025.	1.6	1
71	Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3063-3063.	1.4	1
72	Vulvar melanoma: A monocentric retrospective study on 29 cases.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19036-e19036.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Electrochemotherapy: A treatment with specific intent in specific skin tumorsâ€”Experience from the European Institute of Oncology, Milan.. Journal of Clinical Oncology, 2014, 32, e20042-e20042.	1.6	0
74	Brain metastasis in melanoma patients: Associations with <i>BRAF</i> status and age.. Journal of Clinical Oncology, 2014, 32, e20037-e20037.	1.6	0
75	Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.. Journal of Clinical Oncology, 2015, 33, e20060-e20060.	1.6	0
76	Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients.. Journal of Clinical Oncology, 2015, 33, 9034-9034.	1.6	0
77	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11â€“13 2019, Verona, Italy. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	0